10-Q: Gilead Reports Q2 Growth Amid HIV Strength, Pipeline Shifts

Gilead Sciences reported a 2% increase in total revenues for Q2 2025, driven by strong HIV product sales, while navigating pipeline impairments and ongoing legal challenges.

Summary

• Total revenues increased by 2% to $7.08 billion for the three months ended June 30, 2025, compared to $6.95 billion in the same period of 2024.
• Net income attributable to Gilead was $1.96 billion for Q2 2025, a 21% increase from $1.61 billion in Q2 2024.
• Diluted earnings per share attributable to Gilead rose 21% to $1.56 in Q2 2025, up from $1.29 in Q2 2024.
• For the six months ended June 30, 2025, total revenues increased 1% to $13.75 billion, with net income attributable to Gilead swinging to a positive $3.28 billion from a net loss of $2.56 billion in the prior year period.
• HIV product sales grew 7% to $5.09 billion in Q2 2025, primarily due to higher demand and average realized price for Biktarvy (up 9% to $3.53 billion) and Descovy (up 35% to $653 million).
• Liver Disease product sales decreased 4% to $795 million in Q2 2025, mainly due to lower HCV product sales, partially offset by increased demand for Livdelzi and Hepcludex.
• Veklury product sales declined 44% to $121 million in Q2 2025, attributed to lower rates of COVID-19-related hospitalizations.
• Oncology product sales saw a modest 1% increase to $849 million in Q2 2025, with Trodelvy sales rising 14% to $364 million, while Cell Therapy sales decreased 7% to $485 million.
• A partial impairment charge of $190 million was recognized for the bulevirtide in-process research and development (IPR&D) intangible asset in Q2 2025 due to increased market competition.
• Cash and cash equivalents stood at $5.14 billion as of June 30, 2025, down from $9.99 billion at December 31, 2024.
• Net cash provided by operating activities decreased 27% to $2.58 billion for the six months ended June 30, 2025, primarily due to higher income tax payments, including a final $1.3 billion federal income tax payment for transition tax related to the Tax Cuts and Jobs Act.
• Repaid $1.75 billion of senior unsecured notes that matured in February 2025.
• The Board of Directors authorized a new $6.0 billion stock repurchase program in July 2025, to commence upon completion of the existing $5.0 billion program (which had $1.47 billion remaining as of June 30, 2025).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While core HIV products show strong growth and there are positive regulatory and clinical updates for key pipeline assets (Yeztugo, Trodelvy, seladelpar), significant declines in other product areas (Veklury, Cell Therapy, HCV) and a new IPR&D impairment for bulevirtide temper the enthusiasm. The substantial swing to net income year-to-date is positive, but largely reflects the non-recurrence of major charges from the previous year rather than new, overwhelming positive drivers. Ongoing, high-stakes legal proceedings also present a notable overhang.

Positives

• Total revenues increased by 2% in Q2 2025 and 1% year-to-date, demonstrating continued top-line growth.
• Net income and diluted EPS significantly improved in Q2 2025 (up 21%) and swung from a net loss to a net income year-to-date, primarily due to the absence of large impairment and acquisition charges from the prior year.
• HIV product sales showed strong growth, increasing 7% in Q2 2025 and 6% year-to-date, driven by Biktarvy (up 9% in Q2) and Descovy (up 35% in Q2) due to higher demand and average realized prices.
• Trodelvy sales increased 14% in Q2 2025 and 5% year-to-date, indicating continued market uptake in oncology.
• Received U.S. FDA approval for Yeztugo (lenacapavir) for pre-exposure prophylaxis (PrEP) to reduce HIV risk, offering the first and only twice-yearly HIV PrEP option in the U.S.
• Received a positive opinion from the European Medicines Agency's CHMP recommending lenacapavir for HIV PrEP, and a positive EU-Medicines for All opinion to facilitate access in lowand lower-middle-income countries.
• Announced positive topline results from the Phase 3 ASCENT-03 trial evaluating Trodelvy in 1L metastatic triple-negative breast cancer (mTNBC).
• Entered into an exclusive option and license agreement with Kymera Therapeutics, Inc. for novel oral molecular glue CDK2 degraders with broad oncology potential.
• Received conditional marketing authorization from the European Commission for seladelpar for primary biliary cholangitis (PBC).
• Product gross margin increased to 78.7% in Q2 2025, up from 77.7% in Q2 2024, primarily driven by product mix.
• A new $6.0 billion stock repurchase program was authorized, signaling continued commitment to shareholder returns.

Negatives

• Liver Disease product sales decreased 4% in Q2 2025 and 1% year-to-date, primarily due to lower average realized price and demand for chronic hepatitis C virus (HCV) products.
• Veklury product sales significantly decreased by 44% in Q2 2025 and 45% year-to-date, due to lower rates of COVID-19-related hospitalizations.
• Cell Therapy product sales decreased 7% in Q2 2025 and 5% year-to-date, reflecting ongoing competitive headwinds.
• A partial impairment charge of $190 million was recorded for the bulevirtide IPR&D intangible asset in Q2 2025 due to a potentially more competitive market outside the EU.
• Cash and cash equivalents decreased significantly to $5.14 billion from $9.99 billion at the end of 2024.
• Net cash provided by operating activities decreased 27% for the six months ended June 30, 2025, primarily due to higher income tax payments and operating payments.
• Ongoing legal proceedings, including antitrust, product liability, and qui tam lawsuits, pose potentially significant liabilities and increased expenses, with outcomes inherently uncertain.

Risks

• Inability to sustain or increase sales of HIV products due to market share gains by competitive products, including generics, or failure to introduce new competitive HIV medications.
• Significant challenges in advancing novel and personalized cell therapies like Yescarta and Tecartus, including maintaining robust manufacturing processes, managing adverse side effects, securing sufficient supply of other medications, and potential regulatory restrictions like REMS.
• Reliance on third-party apheresis centers, shippers, couriers, and hospitals for cell therapy logistics, with disruptions potentially leading to product loss and regulatory action.
• Inability to sufficiently increase CAR T-cell therapy manufacturing network capacity to meet growing demand.
• Difficulties and uncertainties inherent in drug development and new product introduction, with a high rate of failure and potential inability to recoup significant R&D, clinical trial, and acquisition-related expenses.
• Challenges in accurately forecasting product sales due to unpredictable demand, fluctuations in purchasing patterns, and wholesaler inventories, potentially leading to product shortages or excess inventory write-offs.
• Significant competition from global pharmaceutical and biotechnology companies, specialized firms, and generic drug manufacturers, affecting pricing and market share.
• Pricing and reimbursement pressures from government agencies and other third parties, including required discounts and rebates, and the potential adverse impact of the Inflation Reduction Act (IRA) and other legislative/regulatory actions on profitability.
• Risks from the importation of products from lower-price markets or the distribution of illegally diverted or counterfeit versions of products, which could harm patients, reputation, and revenues.
• Clinical trial risks, including unfavorable results, delays, and disruptions, such as the clinical hold on HIV treatment trials of GS-1720 and GS-4182, and the failure of the Phase 3 EVOKE-01 study for Trodelvy in NSCLC.
• Inability to obtain materials or supplies necessary for clinical trials or manufacturing, or manufacturing difficulties, delays, or interruptions, including at third-party manufacturers.
• Failure to obtain broad regulatory approvals on a timely basis or to maintain compliance, including if significant safety issues arise for marketed products or product candidates.
• Impact of evolving laws, regulations, and legislative/regulatory actions applicable to the healthcare industry, including anti-kickback, false claims, and data privacy laws, potentially leading to criminal/civil sanctions or increased compliance costs.
• Dependence on the ability to obtain and defend patents and other intellectual property rights, and to operate without infringing on third-party rights, with risks of patent invalidation, litigation, and generic entry.
• Potentially significant liability and increased expenses from ongoing litigation and government investigations, including antitrust, product liability, and qui tam lawsuits, with uncertain outcomes.
• Risks associated with global operations, including foreign currency exchange rate fluctuations, interest rate changes, inflation, anti-bribery laws, restrictive government actions against intellectual property, and changes in trade policies.
• Adverse effects from outbreaks of epidemic, pandemic, or contagious diseases on global operations, supply chains, and demand.
• Negative impacts from climate change and related natural disasters on operations and facilities, as well as increased costs from legal, regulatory, or market measures to address climate change.
• Operational, reputational, financial, and legal risks associated with corporate responsibility matters and ESG goals, including potential failure to achieve goals or comply with evolving disclosure standards.
• Dependence on relationships with third parties for sales, marketing, technology, development, logistics, and commercialization, with risks of poor performance or disputes.
• Failure to attract, develop, and retain highly qualified personnel due to intense competition and potential impacts of workforce adjustments.
• Risks associated with the implementation or upgrade of enterprise resource planning (ERP) and other information systems, potentially leading to operational difficulties, data migration issues, and impacts on internal controls.
• Information system service interruptions or breaches, including cybersecurity incidents, which could lead to legal liability, regulatory action, and adverse effects on business and operations.

Future Outlook

The company anticipates a reduction in income tax payments for the remainder of 2025 due to provisions in the One Big Beautiful Bill (OBBB) Act, which restored immediate expensing of domestic R&D and certain capital expenditures. Future dividends are subject to declaration by the Board of Directors. The company continues to evaluate the potential impact of the Inflation Reduction Act (IRA) on its business, expecting increased payment obligations under the redesigned Part D discount program, limited product prices, and increased rebates, which could reduce profitability. The full impact of new legislation and ongoing legal challenges remains uncertain.

Management Comments

• We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation.
• We regularly review our R&D activities based on unmet medical need and, as necessary, reallocate resources among our internal R&D portfolio and external opportunities that we believe will best support the long-term growth of our business.
• Our capital priorities include: (i) investing in our business and R&D pipeline, (ii) continuing select partnerships and business development transactions, (iii) growing our dividend over time, and (iv) repurchasing shares to offset dilution and opportunistically reduce share count.
• Based on our evaluation of our current position of liquidity, available capital resources and our material cash requirements, we believe that we can satisfy our capital needs for the next 12 months and the foreseeable future.

Industry Context

The biopharmaceutical industry continues to face significant pricing and reimbursement pressures from government agencies and third-party payers, exemplified by the Inflation Reduction Act (IRA) in the U.S. and similar measures in Europe. The sector is also characterized by intense competition, high R&D costs, and the inherent unpredictability of drug development and regulatory approvals. The ongoing shift towards personalized therapies like CAR T-cell treatments presents both opportunities and complex manufacturing and reimbursement challenges. The industry is also adapting to evolving data privacy regulations and increasing scrutiny over patient access and intellectual property, with potential impacts from new legislation like the BIOSECURE Act and the ABC Safe Drug Act.

Comparison to Industry Standards

• The filing does not provide specific comparable company financial results or product performance benchmarks to assess the company's results against global industry standards.
• The company's product gross margin of 78.7% in Q2 2025 is generally strong for the pharmaceutical industry, reflecting the high-value nature of its patented medicines.
• The significant R&D expenses and acquired IPR&D expenses are typical for a large biopharmaceutical company focused on innovation and pipeline expansion, comparable to peers like Merck & Co. or Bristol-Myers Squibb, though specific project comparisons are not detailed.
• The ongoing legal challenges, particularly antitrust and product liability lawsuits related to HIV drugs, are a notable industry-specific risk, with similar litigation impacting other major pharmaceutical companies like Johnson & Johnson and Teva Pharmaceutical Industries Ltd. in the past.

Management Changes

Legal Proceedings

• Ongoing patent litigation against Lupin Ltd., Laurus Labs, and Cipla Ltd. regarding generic versions of Biktarvy, with a single trial scheduled for October 2025.
• Ongoing patent litigation against Aspiro Pharma Ltd. regarding a generic version of Veklury, with a lawsuit filed in July 2025.
• Consolidated class action lawsuits and opt-out cases (including Aetna, Inc.) alleging antitrust and consumer protection violations related to HIV drugs, with appeals pending and trials scheduled for October 2026.
• Lawsuit by the New Mexico Attorney General alleging antitrust and consumer protection violations, currently in jurisdictional discovery.
• Approximately 23,000 active product liability plaintiffs in putative class action and various lawsuits related to Viread, Truvada, Atripla, Complera, and Stribild, alleging kidney, bone, and/or tooth injuries, with trials scheduled for March 2027 and a class certification hearing in August 2025.
• Settled a government investigation with the U.S. Attorney's Office for the Southern District of New York regarding promotional speaker programs for HIV in April 2025, with a $200 million accrual paid in Q2 2025.
• Qui tam lawsuit by a former sales employee alleging False Claims Act violations related to hepatitis C virus (HCV) sales and marketing activities and charitable donations.
• Qui tam lawsuit by Health Choice Advocates, LLC (with Texas Attorney General intervention) alleging Texas Medicare Fraud Prevention Act violations related to clinical educator programs and patient support programs for HCV and HIV.

Stakeholder Impact

• Shareholders: Positive impact from increased net income (due to non-recurrence of prior year charges), strong HIV sales, new product approvals, and a new $6.0 billion stock repurchase program. Negative impact from declines in other product segments, IPR&D impairment, and ongoing legal uncertainties.
• Employees: Potential impact from restructuring charges related to workforce reductions, as well as the ongoing implementation of new ERP systems.
• Customers (Patients/Healthcare Providers): Positive impact from new product approvals like Yeztugo for HIV PrEP and conditional marketing authorization for seladelpar. Potential negative impact from clinical holds on investigational HIV treatments and potential limitations on product access due to pricing and reimbursement pressures.
• Suppliers/Creditors: Debt repayments reduce creditor exposure. Suppliers may be impacted by manufacturing delays or changes in supply chain strategy due to various risks.

Next Steps

• Oral argument scheduled for October 2025 in the appeal of the Phase I verdict in the HIV antitrust litigation.
• Trial scheduled for October 2025 for the Biktarvy generic patent litigation.
• Trial scheduled for October 2026 for the Aetna opt-out lawsuit.
• Trial date set for March 2027 for the first bellwether trial of remaining product liability cases in federal court.
• Hearing scheduled for August 2025 on the plaintiffs' motion to certify a class action in the Missouri product liability case.
• The new $6.0 billion stock repurchase program will commence upon the completion of the 2020 Program.
• The company will continue to evaluate any further changes in its internal control over financial reporting over the course of the implementation of the new ERP and other related systems, scheduled in phases over the next few years.

Key Dates

Recommendation

Gilead's Q2 2025 results present a mixed picture. While the significant swing to net income year-to-date is a positive, it's largely attributable to the absence of substantial impairment and acquisition charges from the prior year, rather than explosive organic growth. The core HIV franchise continues to perform strongly, and there are promising developments in oncology (Trodelvy's growth, positive ASCENT-03 data, Kymera collaboration) and inflammation (seladelpar approval). However, declines in key segments like Veklury, Cell Therapy, and HCV, coupled with a new IPR&D impairment for bulevirtide and the clinical hold on HIV treatment trials, introduce uncertainty regarding future growth drivers. The company faces a substantial overhang from ongoing, high-stakes legal proceedings that could result in significant monetary damages. The new $6.0 billion stock repurchase program is a positive for shareholder returns. For a seasoned investor, the current situation suggests a 'hold' position, awaiting clearer trends in pipeline success, resolution of legal uncertainties, and sustained growth across a broader product portfolio beyond HIV.

Keywords

Biopharmaceutical, HIV, Oncology, Liver Disease, Cell Therapy, Drug Development, Clinical Trials, SEC Filing, Quarterly Report, Pharmaceutical, Biotech, Healthcare, Regulatory Approval, Patent Litigation, Product Sales, Revenue, Net Income, Earnings Per Share, Cash Flow, Debt, Stock Repurchase, Acquisitions, Collaborations, Impairment, Risk Factors